🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  2. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  3. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  4. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  5. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  8. Iptacopan

    Novartis Pharmaceuticals

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule terminated

    1 trial

  9. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  10. KAE609

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  11. KAE609

    Novartis Pharmaceuticals

    Cure Rate

    phase 2 small molecule completed

    1 trial

  12. KAF156

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  13. KAF156

    Novartis Pharmaceuticals

    Acute Uncomplicated Plasmodium Falciparum Malaria

    phase 2 small molecule completed

    1 trial

  14. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  15. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  16. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  17. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  18. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  19. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  20. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  21. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  22. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  23. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  24. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources